Switching to darunavir/ritonavir achieves viral suppression in patients with persistent low replication on first-line lopinavir/ritonavir

AIDS

Volumn 22, Issue 17, 2008, Pages 2405-2407

  Chaix, Marie Laure ^a   Sahali, Sabrinel ^b   Pallier, Coralie ^b   Barrail Tran, Aurélie ^b   Delfraissy, Jean François ^b   Ghosn, Jade ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DARUNAVIR; EMTRICITABINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; TENOFOVIR; VIRUS RNA;

ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PATIENT COMPLIANCE; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS SUPPRESSION;

DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PYRIMIDINONES; RITONAVIR; SULFONAMIDES; VIRUS REPLICATION;

EID: 56549098322     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283177f49     Document Type: Letter

References (14)

1. Eron J, Yéni P, Gathe J, Estrada V, DeJesus E, Statzsewski S, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised noninferiority trial. Lancet 2006; 368:476-482.
2. Ortiz R, DeJesus E, Khanlou H, Voronin E, van Luzen J, Andrade-Villanueva J, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
3. Riddler S, Haubrich R, DiRienzo A, Peeples L, Powderly W, Klingman K, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
4. Yéni P. Medical management of HIV-infected patients. Medecine-Sciences Flammarion ed. Paris; 2008.
5. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005; 49:2314-2321.
6. Katlama C, Esposito R, Gatell J, Goffard J, Grinsztejn B, Pozniak A, et al. Efficacy and safety of TMC114/ritonavir in treatment- experienced HIV patients: 24-week results of POWER 1. AIDS 2007; 21:395-402.
7. Ghosh A, Ramu Sridhar P, Kumaragurubaran N, Koh Y, Weber I, Mitsuya H. Bis-tetrahydrofuran: a privileged ligand for darunavir and a new generation of HIV protease inhibitors that combat drug resistance. ChemMedChem 2006; 1:939-950.
8. Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, Pancharoen C, et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J 2005; 24:874-879.
9. Dierynck I, De Wit M, Gustin E, Keuleers I, Vandermissen J, Hallenberger S, Hertogs K. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol 2007; 81:13845-13851.
10. Flandre P, Delaugerre C, Ghosn J, Chaix ML, Horban A, Girard PM, et al. Prognostic factors of virologic response of lopinavir/ritonavir monotherapy in ARV-naïve patients randomized in the MONARK trial. Antiviral Ther 2008, in press.
11. Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, et al. Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. J Antimicrob Chemother 2008; 62:797-808.
12. Sax P, Xu F, Tisdale M, Elston R. First report of development of resistance to boosted fosamprenavir in an ART-naive subject: virologic and clinic outcome. (poster H-1060). 45th ICAAC. Washington, DC 2005.
13. Conradie F, Sanne I, Venter W, Eron J. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS 2004; 18:1084-1085.
14. Madruga J, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370:49-58.